Sublingual nifedipine in elderly patients: Even a low dose induces myocardial ischaemia

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 5-6, 1999, Pages 404-410

  Ishibashi, Yutaka ^b   Shimada, Toshio ^c   Yoshitomi, Hiroyuki ^c   Sano, Kazuya ^c   Oyake, Nobuyuki ^c   Umeno, Tetsuhiro ^c   Sakane, Takeshi ^c   Murakami, Yo ^c   Morioka, Shigefumi ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c NONE

Author keywords

Elderly; Hypertensive crisis; Left ventricular hypertrophy; Myocardial ischaemia; Sublingual nifedipine

Indexed keywords

LACTIC ACID; NIFEDIPINE;

AGED; AGING; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; MALE; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; AGED; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LACTIC ACID; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NIFEDIPINE;

EID: 0032982286     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03046.x     Document Type: Article

References (29)

1. 1. Beer N, Gallegos I, Cohen A, Klein N, Sonnenblick E, Frishman W. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension. Chest 1981; 79: 571-4.
2. 2. Houston M. Treatment of hypertensive urgencies and emergencies with nifedipine. Am. Heart J. 1986; 111: 963-9.
3. 3. Hayashi H, Iwase M, Aoki T, Yokota M. Assessment of left ventricular function after sublingual administration of nifedipine in patients with moderate to severe hypertension. Cardiovasc. Drugs Ther. 1990; 4: 969-75.
4. 4. Grandi A, Marchesi E, Bertolini A, Finardi G, Venco A. Effect of sublingual nìfedipine on left ventricular diastolic dysfunction in hypertensives: Echo-Doppler study at rest and during handgrip. Acta Cardiol. 1996; 51: 521-8.
5. 5. Psaty B, Heckbert S, Koepsell T. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620-5.
6. 6. Pahor M, Guralnik J, Corti M, Foley D, Carbonin P, Havlik R. Long-term survival and use of antihypertensive medications in older persons. J. Am. Geriatr. Soc. 1995; 43: 1191-7.
7. 7. Furberg C, Psaty B, Meyer J. Nifedipine. Dose-related increase in mortality in palients with coronary heart disease. Circulation 1995; 92: 1326-31.
8. 8. Kaplan N. Systemic hypertension: Therapy. In: Braunwald (ed.). Heart Disease: a Textbook of Cardiovascular Medicine, vol. 5. Saunders, Philadelphia. 1996; 840-62.
9. 9. Harten J, Burggraaf K, Danhof M, Brummelen P, Breimer D. Negligible sublingual absorption of nifedipine. Lancet 1987; ii: 1363-5.
10. 10. Devereux R, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613-18.
11. 11. Ishibashi Y, Shimada T, Nosaka S et al. Effects of heart rate on coronary circulation and external mechanical efficiency in elderly hypertensive patients with left ventricular hypertrophy. Clin. Cardiol. 1996; 19: 620-30.
12. 12. Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertensive emergencies. Lancet 1991; 338: 881 (Letter).
13. 13. O'Mailia J, Sander G, Giles T. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Ann. Intern. Med. 1987; 107: 185-6.
14. 14. Floras J. Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischaemia. Lancet 1988; ii: 994-6.
15. 15. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola S. A prospective, randomized, double-blind, crossover study to compare the efficiency and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-61.
16. 16. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83; 52-60.
17. 17. Anonymous. The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 1997; 157: 332-42.
18. 18. Waters D. Proischemic complications of dihydropyridine calcium channel blocker. Circulation 1991; 84: 2598-600.
19. 19. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989; 80: 59-67.
20. 20. Roine R, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation: A placebo-controlled, double-blind, randomized trial. JAMA 1990; 264: 3171-7.
21. 21. Becker R, Capto R, Ball S, Corrao J, Baker S, Gore J. Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration. Am. Heart J. 1993; 126: 11-14.
22. 22. Vanhoutte P, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80: 1-9.
23. 23. Naeye R. Arteriolar abnormalities with chronic systemic hypertension. Circulation 1967; 35: 662-9.
24. 24. Roberts J, Wearn J. Quantitative changes in the capíllary-muscle relationship in human hearts during normal growth and hypertrophy. Am. Heart J. 1941; 21: 617-21.
25. 25. Wood P. Relative ischemia in the hypertrophied heart. Lancet 1961; i: 696-8.
26. 26. Panza J, Quyyumi A, Brush J. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990; 323: 22-7.
27. 27. Bache R, Homans D, Dai X. Adrenergic vasoconstriction limits coronary blood flow during exercise in hypertrophied left ventricle. Am. J. Physiol. 1991; 260: H1489-94.
28. 1-adrenergic tone. Am. J. Physiol. 1994; 266: 11795-810.
29. 29. Semplicini A, Pessina AC. Nifedipine for hypertensive emergencies. JAMA 1997; 277: 787-8 (Letter).